CD19 and acute lymphoblastic leukemia: In this regard, two phase I studies were launched separately to assess the safety and activity of AFM11 in patients with relapsed or refractory adult B-precursor ALL (ClinicalTrials.gov: NCT02848911) and the ones with R/R CD19-positive B cell NHL (ClinicalTrials.gov: NCT02106091).